{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"181"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"title":"QT: Increase >30 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"181"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"title":"QT: Increase >60 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"173"}],"units":"Participants"}],"title":"QT: New >450 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"177"},{"groupId":"OG002","value":"178"}],"units":"Participants"}],"title":"QT: New >480 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"179"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"title":"QT: New >500 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"180"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"title":"QTcF: Increase >30 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"180"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"title":"QTcF: Increase >60 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"172"},{"groupId":"OG002","value":"174"}],"units":"Participants"}],"title":"QTcF: New >450 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"178"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"title":"QTcF: New >480 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"179"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"title":"QTcF: New >500 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"180"},{"groupId":"OG002","value":"177"}],"units":"Participants"}],"title":"QTcB: Increase >30 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"180"},{"groupId":"OG002","value":"177"}],"units":"Participants"}],"title":"QTcB: Increase >60 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"78"},{"groupId":"OG002","value":"66"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"159"},{"groupId":"OG002","value":"155"}],"units":"Participants"}],"title":"QTcB: New >450 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"175"},{"groupId":"OG002","value":"176"}],"units":"Participants"}],"title":"QTcB: New >480 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"183"},{"groupId":"OG001","value":"180"},{"groupId":"OG002","value":"177"}],"units":"Participants"}],"title":"QTcB: New >500 ms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"159"},{"groupId":"OG002","value":"153"}],"units":"Participants"}],"title":"Heart rate: New <60 bpm"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"175"},{"groupId":"OG002","value":"170"}],"units":"Participants"}],"title":"Heart rate: New >100 bpm"}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"181"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"description":"Newly occurring notable ECG values were reported for QT (millisecond \\[ms\\]), QT corrected interval using Fridericia's correction (QTcF) (ms), QT corrected interval using Bazett's correction formula (QTcB) (ms) and heart rate (beats per minute). Newly occurring was defined as participants not meeting criterion at baseline and meeting criterion post-baseline. Criteria for newly occurring notable ECG values (QT, QTcF, QTcB) were New \\> 450, New \\>480, New \\>500, Increase from baseline \\>30, Increase from baseline \\>60; heart rate: New \\<60, New \\>100.","groups":[{"description":"Participants received 450 milligram (mg) of LGX818 orally once daily (QD) along with 45 mg of MEK162 twice daily (BID) for each 28 day treatment cycle until progressive disease (PD) as confirmed by Blinded Independent Review Committee (BIRC), withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG000","title":"Part 1:LGX818 450 mg QD+MEK162 45 mg BID (Combo 450)"},{"description":"Participants received 300 mg of LGX818 orally once daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG001","title":"Part 1: LGX818 300 mg"},{"description":"Participants received 960 mg of Vemurafenib according to the locally approved prescribing information twice daily for each 28 day treatment cycle until PD as confirmed by BIRC, withdrawal of consent, intolerable toxicity, study discontinuation, lost to follow-up or death.","id":"OG002","title":"Part 1: Vemurafenib 960 mg BID"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who received at least one dose of study medication and have at least one valid post-baseline safety evaluation. Here \"Overall Number of Participants analyzed\" signifies number of participants evaluable for this outcome measure and 'Number analyzed' signifies number of participants evaluable for specified rows.","reportingStatus":"POSTED","timeFrame":"Baseline up to 30 days from last dose of study drug (up to 117.8 months of treatment exposure for LGX818+MEK162 45 mg [combo 450]; up to 111.4 months of treatment exposure for LGX818 300 mg; up to 110.5 months of treatment exposure for Vemurafenib 960 mg)","title":"Part 1: Number of Participants With Newly Occurring Notable Electrocardiogram (ECG) Values","type":"SECONDARY","unitOfMeasure":"Participants"}